Drug
dapagliflozin
Marketed as FARXIGA.
Generic name
dapagliflozin
Brand names
FARXIGA
First FDA approval
2014-01-08
Drug class
Non-GLP-1 diabetes medications
Patient assistance program
Farxiga BMS
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| NDA202293 | FARXIGA | 2014-01-08 | ASTRAZENECA AB |
Manufacturers
ASTRAZENECA AB
Common denial patterns
- Step therapy
- Non-formulary
Specific notes
Brand: Farxiga. SGLT2 with heart-failure indication.
Manufacturer patient assistance
Farxiga BMS: https://www.farxiga.com
Frequently asked questions
Why does insurance commonly deny dapagliflozin?
Step therapy; Non-formulary.
When was dapagliflozin FDA approved?
Earliest FDA approval on record: 2014-01-08.
What brand names are sold as dapagliflozin?
FARXIGA.
Is there a patient assistance program for dapagliflozin?
Yes — Farxiga BMS at https://www.farxiga.com.
What's specific to dapagliflozin?
Brand: Farxiga. SGLT2 with heart-failure indication.
Related
Sources
Appeal a dapagliflozin denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com